FDA & Oncology: SuviCa, CU Boulder and CU Anschutz say the FDA’s written pre-IND feedback for SVC112 is sufficient to support a first-in-human solid-tumor study, with a “reasonable” starting-dose approach. GLP-1 Uptake: A Gallup poll finds about 11% of Americans now take GLP-1s for weight loss, while obesity drops to 36.4% in 2026 (down from 39.9% in 2022). Childhood Metabolic Prevention: A UB analysis of decades of family-based obesity treatment reports it can prevent metabolic disease later in life. Breast Cancer in Young Women: The BCYW Foundation highlights how age changes tumor biology and should shape diagnosis, fertility planning, and treatment. Medicare/Medicaid Access Risks: KFF reports some Medicare beneficiaries on Wellcare “zero-premium” drug plans may lose coverage after premium increases and missed payments. Assisted Living Oversight: A GAO report says assisted living facilities bill at least $12B a year in Medicare/Medicaid dollars, but federal tracking and oversight gaps persist. Public Health—Ebola: WHO says trials are enrolling for Bundibugyo Ebola, aiming to test drugs alongside the outbreak response. Safety & Recalls: FDA recall coverage includes heart/kidney meds; Kao USA recalls select Oribe scalp shampoo lots over bacterial contamination. Workforce & Care Delivery: Mentavi Health adds an enterprise partnerships hire to expand adult ADHD diagnostic and mental wellness care pathways. Policy Watch: Senators urge limits on federal funds that block states/Tribes from regulating online prediction markets.